UBS AM
SYRE icon

UBS AM’s Spyre Therapeutics SYRE Stock Holding History

UBS AM’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.3M Buy
522,071
+314,757
+152% +$23M 0.01% 680
2026
Q1 		$10.5M Buy
207,314
+145,098
+233% +$5.47M ﹤0.01% 1168
2025
Q4 		$2.04M Buy
62,216
+22,718
+58% +$594K ﹤0.01% 1871
2025
Q3 		$662K Sell
39,498
-46,204
-54% -$753K ﹤0.01% 2116
2025
Q2 		$1.28M Buy
85,702
+33,564
+64% +$497K ﹤0.01% 2322
2025
Q1 		$841K Buy
52,138
+3,157
+6% +$65.7K ﹤0.01% 2375
2024
Q4 		$1.14M Buy
48,981
+22,540
+85% +$661K ﹤0.01% 2308
2024
Q3 		$778K Sell
26,441
-3,680
-12% -$102K ﹤0.01% 2498
2024
Q2 		$708K Buy
+30,121
New +$1.02M ﹤0.01% 2525

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

UBS AM's SYRE Position: Q2 2026 in Review

UBS AM increased its Spyre Therapeutics (SYRE) stake by 152% in Q2 2026, buying an estimated $23M and bringing the position to 522,071 shares worth $46.3M. The position accounts for 0.01% of the portfolio, ranked #680.

UBS AM first reported a position in SYRE in Q2 2024 and has held it in 9 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • UBS AM held 522,071 shares of Spyre Therapeutics worth $46.3M as of Q2 2026.
  • UBS AM bought 314,757 Spyre Therapeutics shares in Q2 2026, an estimated $23M.
  • Spyre Therapeutics made up 0.01% of UBS AM's portfolio in Q2 2026, its #680 holding.
  • UBS AM first reported a position in Spyre Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.